Clinical trial · Observational
Bevacizumab Treatment and Retinal Vessel Monitoring
Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy
NCT00740168CI-TRIAL-00020606BevaRetcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- TG
- description
- Bevacizumab treatment group with metastasized cancer
- interventionNames
- Drug: bevacizumab treatment
Primary outcomes (1)
- measure
- Diameter of retinal vessels and dynamic vessel reaction
- timeFrame
- Measurements before and after administration
Secondary outcomes (1)
- measure
- Baroreflex sensitivity, heart frequence variability, reaction to handgrip test
- timeFrame
- Measurements before and after administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients who wish and need bevacizumab treatment for underlying disease Exclusion Criteria: * previous bevacizumab treatment * known eye disease, eye surgery or eye trauma in history * myopia \>-2.0 dpt * hyperopia \> +2.0 dpt. * relevant media opacity of the lens * acute heart disease, ischemic insult, proven coronary heart disease * cardiac arrhythmia or vessel anomalies * seizure disorder or episode in history * migraine * treatment with corticosteroids within 4 weeks before study inclusion * intake of vasoactive drugs like AT-1 or glitazone * pregnancy
References
Publications (1)
- DERIVEDReimann M, Folprecht G, Haase R, Trautmann K, Ehninger G, Reichmann H, Ziemssen F, Ziemssen T. Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med. 2013 May 13;5(1):7. doi: 10.1186/2040-7378-5-7. PMID 23668549